The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Mechanisms of small cell lung cancer metastasis
Open accessAbstract
Metastasis is a major cause of morbidity and mortality in cancer patients. However, the molecular and cellular mechanisms underlying the ability of cancer cells to metastasize remain relatively poorly understood. Among all solid tumors, small cell lung cancer (SCLC) has remarkable metastatic proclivity, with a majority of patients diagnosed with metastatic disease. Our understanding of SCLC metastasis has been hampered for many years by the paucity of material from primary tumors and metastases, as well as the lack of faithful pre-clinical models. Here, we review recent advances that are helping circumvent these limitations. These advances include methods that employ circulating tumor cells from the blood of SCLC patients and the development of diverse genetically engineered mouse models of metastatic SCLC. New insights into the cellular mechanisms of SCLC metastasis include observations of cell fate changes associated with increased metastatic ability. Ongoing studies on cell migration and organ tropism promise to expand our understanding of SCLC metastasis. Ultimately, a better molecular understanding of metastatic phenotypes may be translated into new therapeutic options to limit metastatic spread and treat metastatic SCLC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244 · cited 1×
“Over the past 30 years, the only major change to standard chemotherapy and radiation treatments has been the recent approval of immune checkpoint inhibitors, which extend survival by several months (Antonia et al , 2016; Horn et al , 2018; Ready et al , 2020; Rudin et al , 2020).”
Immune cell promotion of metastasis
Kitamura, T., Qian, B.-Z., & Pollard, J. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3789 · Cited by 1,158
Long‐term expanding human airway organoids for disease modeling
Sachs, N., Papaspyropoulos, A., Zomer‐van Ommen, D. D., Heo, I., Böttinger, L., Klay, D., Weeber, F., Huelsz‐Prince, G., Iakobachvili, N., Amatngalim, G. D., et al. (2019) · The EMBO Journal · doi:10.15252/embj.2018100300 · Cited by 1,082 · cited 1×
“For instance, new protocols to grow organoids derived from primary lung tumors, including neuroendocrine tumors (Sachs et al , 2019; Kawasaki et al , 2020), may provide new ways to investigate cell – cell interactions important for the dissemination of SCLC.”
Rudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00793 · Cited by 760 · cited 1×
“Over the past 30 years, the only major change to standard chemotherapy and radiation treatments has been the recent approval of immune checkpoint inhibitors, which extend survival by several months (Antonia et al , 2016; Horn et al , 2018; Ready et al , 2020; Rudin et al , 2020).”
Meuwissen, R., Linn, S. C., Linnoila, R. I., Zevenhoven, J., Mooi, W. J., & Berns, A. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00220-4 · Cited by 643 · cited 4×
“Approximately half of the mice develop metastases to the lymph nodes, liver, and a variety of other organs including the spleen and the kidneys (Meuwissen et al , 2003; McFadden et al , 2014) ( (Schaffer et al , 2010; Cui et al , 2014; Gazdar et al , 2015; Jia et al , 2018).”
InfluentialReady, N. E., Ott, P. A., Hellmann, M. D., Zugazagoitia, J., Hann, C. L., de Braud, F., Antonia, S. J., Ascierto, P. A., Moreno, V., Atmaca, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.10.004 · Cited by 315 · cited 1×
“Over the past 30 years, the only major change to standard chemotherapy and radiation treatments has been the recent approval of immune checkpoint inhibitors, which extend survival by several months (Antonia et al , 2016; Horn et al , 2018; Ready et al , 2020; Rudin et al , 2020).”
An Organoid Biobank of Neuroendocrine Neoplasms Enables Genotype-Phenotype Mapping
Kawasaki, K., Toshimitsu, K., Matano, M., Fujita, M., Fujii, M., Togasaki, K., Ebisudani, T., Shimokawa, M., Takano, A., Takahashi, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.023 · Cited by 238 · cited 1×
“For instance, new protocols to grow organoids derived from primary lung tumors, including neuroendocrine tumors (Sachs et al , 2019; Kawasaki et al , 2020), may provide new ways to investigate cell – cell interactions important for the dissemination of SCLC.”
Stem Cell-Based Human Blood–Brain Barrier Models for Drug Discovery and Delivery
Aday, S., Cecchelli, R., Hallier-Vanuxeem, D., Dehouck, M. P., & Ferreira, L. (2016) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.01.001 · Cited by 169
Jacoby, J. J., Erez, B., Korshunova, M. V., Williams, R. R., Furutani, K., Takahashi, O., Kirkpatrick, L., Lippman, S. M., Powis, G., O'Reilly, M. S., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181dc211f · Cited by 84
Cited by
Megyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Hoetzenecker, K., Schwendenwein, A., Boettiger, K., et al. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 369
Photodynamic therapy of lung cancer, where are we?
Crous, A., & Abrahamse, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.932098 · Cited by 38
“, 2011) and has the tendency to metastasize and grow rapidly (Ko et al., 2021).”
Background
Metadata
- Authors
- Ko, J., Winslow, M. M., & Sage, J.
- Venue
- EMBO Molecular Medicine
- Published
- 2020-12-09
- Volume
- 13
- Issue
- 1
- Pages
- e13122-e13122
- ISSN
- 1757-4676 (ISSN-L)
- 1757-4684
- OpenAlex
- W3111586032
- Cited by
- 234
- References
- 9
- FWCI
- 9.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.